| First Author | Zhang L | Year | 2019 |
| Journal | Biochim Biophys Acta Mol Basis Dis | Volume | 1865 |
| Issue | 9 | Pages | 2157-2167 |
| PubMed ID | 31034991 | Mgi Jnum | J:277797 |
| Mgi Id | MGI:6323927 | Doi | 10.1016/j.bbadis.2019.04.013 |
| Citation | Zhang L, et al. (2019) The db mutation improves memory in younger mice in a model of Alzheimer's disease. Biochim Biophys Acta Mol Basis Dis 1865(9):2157-2167 |
| abstractText | Alzheimer's disease (AD) is the most common age-related neurodegenerative disease, while obesity is a major global public health problem associated with the metabolic disorder type 2 diabetes mellitus (T2DM). Chronic obesity and T2DM have been identified as invariant risk factors for dementia and late-onset AD, while their impacts on the occurrence and development of AD remain unclear. As shown in our previous study, the diabetic mutation (db, Lepr(db/db)) induces mixed or vascular dementia in mature to middle-aged APP(DeltaNL/DeltaNL) x PS1(P264L/P264L) knock-in mice (db/AD). In the present study, the impacts of the db mutation on young AD mice at 10weeks of age were evaluated. The db mutation not only conferred young AD mice with severe obesity, impaired glucose regulation and activated mammalian target of rapamycin (mTOR) signaling pathway in the mouse cortex, but lead to a surprising improvement in memory. At this young age, mice also had decreased cerebral Abeta content, which we have not observed at older ages. This was unlikely to be related to altered Abeta synthesis, as both beta- and gamma-secretase were unchanged. The db mutation also reduced the cortical IL-1beta mRNA level and IBA1 protein level in young AD mice, with no significant effect on the activation of microglia and astrocytes. We conclude that the db mutation could transitorily improve the memory of young AD mice, a finding that may be partially explained by the relatively improved glucose homeostasis in the brains of db/AD mice compared to their counterpart AD mice, suggesting that glucose regulation could be a strategy for prevention and treatment of neurodegenerative diseases like AD. |
